<DOC>
	<DOCNO>NCT01451736</DOCNO>
	<brief_summary>This study determine efficacy oral risperidone ( Risperdal ) versus long-acting injectable paliperidone palmitate ( Invega Sustenna ) treat people first-episode schizophrenia .</brief_summary>
	<brief_title>Oral Risperidone Versus Injectable Paliperidone Palmitate Treating First-Episode Schizophrenia</brief_title>
	<detailed_description>Schizophrenia severely disable brain disorder . People schizophrenia often experience hallucination , delusion , think disorder , movement disorder . Proper treatment first-episode schizophrenia may increase chance control disease progression long-term basis . People experience first episode schizophrenia responsive treatment chronic schizophrenia , also susceptible adverse treatment side effect . Atypical antipsychotic medication show produce few extrapyramidal side effect older `` typical '' antipsychotic . Oral risperidone atypical antipsychotic medication commonly use control symptom schizophrenia . Adherence prescribe oral medication continue major clinical issue . This study determine effectiveness oral risperidone versus long-acting injectible alternative , paliperidone palmitate , treat people first-episode schizophrenia . Impact clinical symptom cognitive functioning examine . Participants open label study randomly assign receive either orally administer risperidone long-acting paliperidone palmitate administer via injection . Participants assign oral risperidone receive medication dos determine optimal study psychiatrist . Participants assign long-acting risperidone receive injection paliperidone palmitate every 4 week . Dosages adjust necessary achieve optimal dosage . Following 2 3 month achieve outpatient oral risperidone dosage stabilization , randomize medication condition begin participant monitor 1 year . Study visit occur weekly throughout study . They include psychiatrist monitor medication response side effect ; group therapy meeting focus everyday living skill ; family education schizophrenia ; individual meeting case manager counsel evaluation schizophrenia symptom , work recovery , social functioning .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . A first episode psychotic illness occur occur within last 2 year ; 2 . A diagnosis Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) schizophrenia , schizoaffective disorder , depress type , schizophreniform disorder ; 3 . Between 18 45 year age . 1 . Neurological disorder ( e.g. , epilepsy ) significant head injury ; 2 . Significant alcohol substance use disorder within six month prior first episode evidence substance abuse trigger psychotic episode make schizophrenia diagnosis ambiguous ; 3 . Mental retardation , i.e . premorbid intelligence quotient ( IQ ) less 70 ; 4 . Insufficient acculturation fluency English language avoid invalidate research measure think , language , speech disorder verbal ability ; 5 . Residence likely outside commute distance University California , Los Angeles ( UCLA ) Aftercare Research Program ; 6 . Patient show inadequate response adequate previous trial oral longacting injectable risperidone , paliperidone , paliperidone palmitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>First-episode Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder , Depressed Type ( recent-onset )</keyword>
	<keyword>Schizophreniform Disorder</keyword>
	<keyword>oral risperidone</keyword>
	<keyword>long-acting injectable paliperidone palmitate</keyword>
	<keyword>functional outcome</keyword>
</DOC>